Filing Details

Accession Number:
0001127602-12-003921
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-02-03 14:56:06
Reporting Period:
2012-02-01
Filing Date:
2012-02-03
Accepted Time:
2012-02-03 14:56:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875045 Biogen Idec Inc. BIIB Biological Products, (No Disgnostic Substances) (2836) 330112644
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1409601 J Paul Clancy Biogen Idec Inc.
133 Boston Post Road
Weston MA 02493
Executive Vp And Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-02-01 13,000 $43.50 34,168 No 4 M Direct
Common Stock Acquisiton 2012-02-01 8,400 $67.57 42,568 No 4 M Direct
Common Stock Disposition 2012-02-01 13,000 $120.00 29,568 No 4 S Direct
Common Stock Disposition 2012-02-01 8,400 $120.00 21,168 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2012-02-01 13,000 $0.00 13,000 $43.50
Common Stock Stock Option (Right to Buy) Disposition 2012-02-01 8,400 $0.00 8,400 $67.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-02-06 No 4 M Direct
0 2015-02-17 No 4 M Direct
Footnotes
  1. Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
  2. This represents the weighted average price for shares sold at a range between $120.00 (low) and $120.01 (high).
  3. Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
  4. The stock option becomes exercisable in four(4) equal annual installments, commencing one year after the grant date of 02/06/04.
  5. The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/17/05.